CANACCORD GENUITY MUSCULOSKELETAL CONFERENCE 2023 MARCH 7, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking ...

公司业务发展 - 公司是一家全球关节保护公司，致力于在早期干预骨科护理领域取得有意义的进展[148] - 公司在2022年加强了在OA疼痛管理领域的美国市场份额，单次注射Monovisc和多次注射Orthovisc[152] - Anika的新一代非阿片类单次注射HA产品Cingal在第三阶段临床试验中成功实现了主要终点，展示了在26周内对OA疼痛的优越性[154] 财务表现 - 2022年12月31日，公司的净亏损为1490万美元，每股摊薄亏损1.02美元，较上一年的净收入410万美元，每股摊薄收入0.28美元有所下降[169] - 2022年12月31日，调整后的毛利润为1.03亿美元，占总收入的66%，较2021年的9810万美元有所增加[171][171] - 2022年12月31日，调整后的EBITDA为1,2601万美元，较2021年的1,6432万美元有所下降[175] - 2022年12月31日，调整后的净亏损为706.3万美元，每股摊薄亏损0.49美元，较2021年的371万美元有所增加[177] - 2021年，公司的营收为1.48亿美元，较2020年的1.3亿美元增长13%[178] - 2021年，OA疼痛管理产品系列的收入增长了8%，关节保护和修复产品系列的收入增长了23%，非骨科产品系列的收入增长了20%[179] - 2021年，公司的毛利润为8290万美元，毛利率为56%，较2020年的6900万美元、53%有所增加[182] - 2021年，公司的运营费用为8032.8万美元，较2020年的9734.8万美元减少了1702万美元[178] - 2021年，公司的净收入为413.4万美元，较2020年的2398.2万美元有所增加[178] - 2021年研发支出为2,730万美元，同比增长17%[183] - 2021年销售、一般和管理费用为7,410万美元，同比增长23%[184] - 2021年净收入为410万美元，每股摊薄收益为0.28美元，较去年同期净亏损24,000万美元有所增长[188] 会计处理 - 我们使用收入法来确定商标的公允价值[201] - 我们通过五步模型来确定销售收入，包括商业合作伙伴、医院和ASCs以及分销商[202] - 我们的库存主要以标准成本和净可变现价值为基础，使用先进先出法[205]

Q4 AND YEAR-END 2022 EARNINGS CALL MARCH 6, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements wit ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President & CEO Mike Levitz - EVP & CFO Conference Call Participants George Sellers - Stephens Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Greetings, and welcome to Anika's Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants George Sellers - Stephens Incorporated Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Good evening, ladies and g ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants James Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Sec ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President and CEO Mike Levitz - EVP, CFO and Treasurer Conference Call Participants Chris Cooley - Stephens Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namarof ...